Among the medicines listed for AML; Lymphoma; Prostate, Mitoxantrone has a defined role in Acute leukemias and lymphomas; palliative metastatic castration-resistant prostate cancer in selected settings. Intercalates DNA and inhibits topoisomerase II. Its pharmacological class is Anthracenedione. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. The database categorizes it as Chemotherapy; Topoisomerase Inhibitor and records regimen examples such as FLAG-IDA variants; lymphoma/leukemia salvage; selected prostate cancer regimens. These combinations indicate how the agent fits into broader treatment programs rather than functioning as a universal therapy for every cancer in the tumor group. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Clinical interpretation should include the disease stage, histology, treatment history, and any molecular or receptor feature expressly named in the indication. The mechanism is useful for understanding why those selection criteria matter and why another drug from the same broad category may not be interchangeable. This summary has been written for an oncology medicines reference database and does not attempt to prescribe therapy for an individual patient. Because labels and guideline-supported uses can change, current product information should be checked when the entry is applied clinically.